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Background: The HIV envelope (Env) promotes viral entry in the host cell. During this process, Env undergoes
several conformational changes to ensure its function. At the same time, the gp120 component of Env is the
protein of the virus presenting the largest genetic diversity. Understanding how the virus maintains the balance
between the competing requirements for maintenance of functionality and antigenic variation of this protein is
central for the comprehension of its strategies of evolution and can highlight vulnerable aspects of its replication
cycle. We focused on the variable domains V1 and V2 of the HIV-1 gp120 that are involved in conformational
changes and are critical for viral escape from antibody neutralization.
Results: Despite the extensive sequence diversity found in the epidemic for these regions and their location on the
external face of the protein, we observed that replacing V1V2 of one primary isolate with that of another severely
interferes with Env functionality in more than half of the cases studied. Similar results were obtained for intra- and
intersubtype chimeras. These observations are indicative of an interference of genetic diversity in these regions with
Env functionality. Therefore, despite the extensive sequence diversity that characterizes these regions in the epidemic,
our results show that functional constraints seem to limit their genetic variation. Defects in the V1V2 chimeras were not
relieved by the insertion of the V3 region from the same isolate, suggesting that the decrease in functionality is not
due to perturbation of potential coevolution networks between V1V2 and V3. Within the V1V2 domain, the sequence
of the hypervariable loop of the V1 domain seems to be crucial for the functionality of the protein.
Conclusions: Besides the well-documented role of V1V2 in the interplay with the immune response, this work shows
that V1 is also involved in the selection of functional envelopes. By documenting a compromise between the
opposing forces of sequence diversification and retention of functionality, these observations improve our
understanding of the evolutionary trajectories of the HIV-1 envelope gene.
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Genetic diversification and natural selection are the es-
sential processes that prompt adaptation to the environ-
ment. Living under the constant pressure imposed by
the immune system constrains viruses, and in particular
those producing persistent infections. These constraints
involve perpetual change of their epitopes while preserv-
ing the functionality of the individual genes and gene
networks. The human immunodeficiency virus type I* Correspondence: m.negroni@ibmc-cnrs.unistra.fr
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reproduction in any medium, provided the or(HIV-1) constitutes one of the most well-characterized
examples of genetic variation, with an impressive se-
quence diversity documented for this virus in the AIDS
pandemic [1]. The extent of such genetic diversity in
HIV-1 implies that the viral components are highly tol-
erant of sequence variation. The HIV-1 component pre-
senting the highest degree of sequence diversity is the
extra-viral part of the envelope protein, comprising the
glycoprotein gp120. The HIV-1 envelope enables viral
entry into the target cell, a process mediated by recogni-
tion of the CD4 receptor and CCR5 or CXCR4 corecep-
tors at the surface of the cell membrane [2-9]. HIV-1 Env
is composed of glycoproteins gp41 and gp120, which formal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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keeps the Env machinery associated with the viral mem-
brane, whereas the surface gp120 is located completely on
the outside face of the viral lipid bilayer. Trimers of this
heterodimer constitute the functional form that mediates
viral entry [10]. After binding to the CD4 molecule
present at the surface of target cells [4,9], gp120 under-
goes conformational changes that expose a cryptic binding
site for the coreceptor molecule [5-7,11]. The variable
regions V1, V2, and V3 have all been implicated in the
conformational changes required to expose the corecep-
tor binding site [12-15]. Upon interaction with the core-
ceptor, further conformational changes occur, leading to
the exposure of the fusion peptide with the gp41 ecto-
domain and the transition of gp41 into a pre-hairpin
intermediate [16-19]. These changes will then promote
the fusion of the viral and target cell membranes [20-22].
The need for these conformational transitions requires a
remarkable flexibility of the protein and its functional do-
mains that are formed in the ternary and, possibly, the
quaternary structure of the protein [23,24].
An ideal means to conciliate the opposing requirements
of antigenic variation and the preservation of functionality
of a protein requires the complete functional separation
of its domains. This can ensure the achievement of
these two goals through their structural independence.
Thus, the regions that are more accessible to the immune
system are free to undergo extensive sequence diversifi-
cation to counteract the immune response. On the other
hand, the regions that are responsible for enzymatic
reactions or structural interactions could remain essen-
tially unvaried, preserving their functionality. gp120 is
evocative of such a task specialization. This protein is
organized in five constant regions (C) that alternate
with five variable regions (V) [25,26]. This organization
partially reflects the spatial arrangement of the protein,
in that the V regions are located mostly on the external
part of the protein, whereas the C regions are globally
located more in the internal portion [27,28]. The loca-
tion of the V regions in the external part of the protein
[27-29] and their extensive genetic diversity [1] imply
that one of their functions is to serve as a decoy for the
immune response, whereas the more conserved internal
core provides the scaffold that stabilizes the structure
of the protein [30,31]. In parallel with this architectural
organization, the virus has developed various other strat-
egies to escape the immune response raised by the host.
Among these strategies is the masking of the coreceptor
binding site through the presence of the variable loops
until the virus has docked onto the target cell. The pres-
ence of multiple N-linked glycosylation sites in gp120
[27,29,32,33], and particularly in its variable regions,
constitutes another means of restricting recognition of
the protein by the antibodies raised by the host. In addition,the variable domains evolve in natural infections, with
changes in size, sequence, and glycosylation pattern
occurring during disease progression, thus increasing
neutralization resistance [9,18,32,34-37]. The variable
domains have also been shown to be involved in some
essential processes for Env functionality, such as the
formation of the coreceptor binding site [32,38-42] or
the role of V3 in the determination of the viral tropism
[39]. Despite their high genetic variability, conserved
structural features of these regions are also beginning
to emerge, suggesting that the V regions may play other
important roles in the functionality of gp120 [43]. These
conserved structural motifs essentially concern the V1V2
and V3 regions. Indeed, V3 is considered as the most
conserved of the variable regions and presents conserved
base and tip of the loop with variable intervening regions
[44]. For the V1V2 region, an organization in four con-
served β-sheets with two intervening variable loops has
been described [31].
V1 and V2 are the most variable regions in gp120,
and their predominant involvement in the development
of neutralizing antibodies has been described in several
studies, particularly after the development of the RV144
vaccine trial, which elicited antibodies against this region
[45-47]. Studies on the functional role of these regions
were generally conducted with deletion or mutation of
these regions. It was shown that mutants with either V1,
V2, or both deleted loops did not abrogate the capacity
of the virus to replicate in tissue culture, even if these
mutants were less efficient than their wild-type counter-
parts [15,48-53]. Here, through the study of chimeras in
which the variable regions V1V2 were replaced using
primary isolates from different subtypes, we addressed
the issue of the importance of these regions, in particu-
lar the poorly studied V1 loop, in the maintenance of
the functionality of the envelope protein.
Results
The replacement of the homologous structural V1V2
region of gp120 between primary isolates affects Env
functionality
In a previous work, we showed that when recombination
between primary isolates of HIV-1 group M led to a re-
placement of a region that included the V1V2 portion
of gp120, recombinant envelopes displayed a marked
decrease in functionality [54]. To better understand this
observation and investigate the impact of genetic vari-
ation in the V1V2 region on the functionality of the
HIV-1 envelope, chimeric envelopes were generated by
replacing the V1V2 region of one primary isolate with
the corresponding region of other primary isolates. The
V1V2 region is organized in four β-sheets and two loops
as indicated in Figure 1A [31]. The β-sheets are more
fairly conserved than the loop portions, as indicated in
Figure 1 (See legend on next page.)
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Figure 1 Strategy and sequences used in the present study. Panel A. Representation of the V1V2 region according to the structure of McLellan et al.
[31]. The four β-sheets are indicated by yellow arrows, the unstructured loops V1 and V2 are indicated in red and blue, respectively, whereas the small
loop connecting β-sheets B and C is drawn in green. The start of the β-sheet B differed between the two isolates used in McLellan et al. (CAP 45 and
ZM109). Here, we considered the minimal size of the β-sheet B, which is the one from the isolate CAP 45. Panel B. Amino acid sequence alignment of
the V1V2 region for the isolates used to generate the main five chimeras characterized in this study. Identical residues are in a yellow background, and
hyphenations indicate gaps in the alignment. The C residues that define the borders of the V1 and V2 regions are indicated in red. The delimitations of
the V1 and V2 regions is given, as a reference, at the bottom of the drawing. The vertical gray bars define the borders of the structural domains
defined by McLellan and colleagues [31]. The four β-sheets are indicated as βA, B, C and D, while the region indicated as "connection" corresponds to
the mini loop connecting β-sheets B and C (see text for details). Alignments were performed using MUSCLE 3.8 [55]. Panel C. Schematic representation
of the chimeric HIV-1 envelopes used in this study. The structure of the HIV-1 envelope gene is given at the top as a reference, with the constant and
variable regions of the gp120 region in green and yellow, respectively. The fusion peptide (FP), helix N (HN), helix C (HC), transmembrane domain (TM)
and cytoplasmic tail (CT) of the gp41 are indicated in gray.
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we will refer to V1V2 as a "region", to V1 or V2 as a
"domain", and to the hypervariable loops as "loops".
We focused on the study of chimeras derived from
isolates of HIV-1 belonging to the phylogenetic group
responsible for the vast majority of the infections, group
M. This group is further subdivided in various subtypes
(A-D, F-H, J, and K) [56]. Primary isolates belonging to
subtypes A, B, C, and G were employed in the present
study. These subtypes were frequently found to produce
intersubtype recombinant forms in the epidemics [57].
We initially chose isolates that we previously character-
ized in the study on genetic recombination mentioned
above [54,58-60]. The sequences of the V1V2 region of
these isolates are shown in Figure 1B. As an example, we
refer to the isolates as "isolate A", "isolate A1"… for iso-
lates that belong to subtype A of group M, as "isolate B"
for the isolate from subtype B used, and so on. This no-
menclature is not intended to generalize the behavior of
a given isolate to all the isolates of the same subtype.
The chimeric envelopes used in this study are referred
to as XYX, where X indicates the isolate providing the
backbone (called the receiver) and Y indicates the isolate
providing the insert, called the donor (Figure 1C). As an
example, the chimera AGA V1V2 is comprised of the
envelope of an isolate from subtype A carrying a V1V2
region from an isolate of subtype G (see Methods for
details on the sequences used throughout the study).
The functionality of the chimeric envelopes was defined
by their ability to mediate viral entry into target cells.Table 1 Amino acid sequence identity of the structural compo
chimeras V1 V2 β-A V1 loop
A/B 52.5 50.0 100.0 36.7
A/C 46.9 63.0 85.7 31.8
A/G 38.2 56.5 100.0 12.5
B/C 37.5 54.5 85.7 23.3
B/G 42.5 52.5 100.0 23.3
Results are based on the structure described in reference [31]. The values of sequen
Figure 1A. The similarity table based on the Blosum62 matrix is provided in AdditiopNL4.3-Env--Luc+ virions complemented by the individ-
ual chimeric envelopes are used for this test, as described
in Methods. To understand whether the replacement of
the V1V2 region altered the functionality of the receiver
protein, the functionality of each chimera was compared
with that of the corresponding wild-type receiver protein
(a comparison of the functionality of the chimeras with
respect to the wild-type donor protein is also provided,
in Additional file 2: Table S2).
A significant decrease in viral entry was observed in
three of the cases studied, with a drop in functionality to
less than 30% for the ACA chimeras and to almost un-
detectable levels for the BCB and BGB chimeras, as indi-
cated in Figure 2A. For the AGA chimeras, only a modest
decrease was observed (functionality higher than 70% of
the corresponding wild-type receiver protein; p = 0.10),
whereas the ABA chimera displayed a slight (1.4 fold;
p = 0.27) increase in functionality with respect to the
wild-type A backbone protein. Differences in the level
of functionality cannot be accounted for by differences
in the levels of expression of the chimeras as shown by
Western blot (Additional file 3: Figure S1).
Given the overall extensive genetic diversity present in
V1V2 in the viral population and their location on the
external face of the protein, it was expected that these
regions could be easily exchanged. The strong decrease
in functionality observed in three of the five V1V2 chi-
meras was, therefore, unexpected.
To extend these observations to the case of intrasub-
type chimeras, we constructed six intrasubtype V1V2nents of the V1V2 region for the chimeras
β-B connect β-C V2 loop β-D
100.0 33.3 54.5 38.5 60.0
77.8 100.0 72.7 42.9 80.0
100.0 66.7 45.5 38.1 100.0
77.8 33.3 81.8 33.3 40.0
100.0 33.3 72.7 20.0 60.0
ce identity are given in percentage. The individual regions are defined as in
nal file 1: (Table S1).
Figure 2 Functionality of the V1V2 chimeric envelopes in viral
entry tests. Panel A. Functionality of the V1V2 chimeras. The level of
functionality of the V1V2 chimeras in viral entry tests for the main 5
chimeras characterized in this study is given relative to the
functionality of the wild-type receiver protein (Env from the isolate of
subtype A for the ABA, ACA, and AGA chimeras, and from subtype B
for BCB and BGB chimeras). Values are the average of 4 to 5
independent experiments. The asterisk indicates a significant difference
(p < 0.001) in the functionality of the chimera with respect to the
corresponding wild-type receiver protein. Panel B. Functionality of V1V2
intra- and intersubtype chimeras. The functionality of six intrasubtype
(gray circles) and six intersubtype (white circles) chimeras is given
relative to the functionality of the corresponding wild-type receiver
Env. Thicker circles indicate significant differences (p < 0.001) in the
functionality of the chimera with respect to the corresponding wild-
type receiver protein. Values are the average of 3 to 5 independent
experiments. Details regarding the sequences used for this part of the
study are given in the Methods section.
Table 2 Sequence identity and entry efficiency of V1V2
inter- and intrasubtypes chimeras
Sequence identity (%) Viral entry (%) SD (%)
Intersubtype A/B 51.2 141.5 52.2
A/C 56.4 29.1 9.2
A/G 48.8 72.5 23.0
B/C 46.4 1.1 1.0
B/C3 45.7 0.5 0.3
B/G 47.5 3.2 3.6
Intrasubtype A/A1 66.7 69.4 38.6
A/A2 62.8 115.9 20.1
C/C1 60.0 1.2 0.6
C/C2 50.0 2.8 1.5
C/C3 57.5 0.9 0.6
G/G1 54.1 257.1 27.4
In all cases, the values are given relative to those observed for the corresponding
wild-type receiver protein. The results for viral entry represent the mean values
derived from 3 to 5 independent experiments. SD, standard deviation.
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of subtype G; see Methods). To generate comparable
datasets for intra- and intersubtype chimeras, we alsogenerated an additional intersubtype chimera (between
isolates from subtype B and C; see Methods). The amino
acid sequence identity ranged from 45.7 to 56.4% among
the intersubtype chimeras and from 50.0 to 66.7% among
the intrasubtype chimeras (Table 2). Seven of the twelve
chimeras displayed significantly decreased functionality
(p < 0.005) with respect to the corresponding wild-type
proteins (4 inter- and 3 intrasubtype chimeras), with a
drop in functionality for 6 of the chimeras below 5%
of that of the corresponding wild-type receiver Env,
while the seventh showed a residual functionality of 29%
(Figure 2B, and Table 2). The remaining chimeras exhib-
ited levels of functionality that were in the range of
those of the corresponding wild-type receiver proteins,
except for the intrasubtype chimera GG1G, which dis-
played a 2.4-fold increase. The average level of function-
ality of the intersubtype chimeras (41 ± 56%) was lower
than that of the intrasubtype chimeras (73 ± 95%). How-
ever, given the large range of the values observed within
intra- as well as intersubtype chimeras, the difference
between the two datasets was not significant (p = 0.57).
The decrease in functionality that we originally ob-
served by replacing V1V2 between intersubtype isolates
is therefore also found when considering genetically
closer isolates.
The variable domain V3 does not influence the
functionality of the V1V2 chimeras
Several lines of evidence suggest that V1V2 and V3
are in close spatial proximity and that this proximity
is involved in epitope masking from the immune re-
sponse [61-63]. To understand whether the decrease in
functionality observed for the V1V2 chimeras was due
to the phylogenetic discordance between V1V2 and V3,
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the same isolate. In this case, a recovery in functionality
would suggest that V1V2 had coevolved with V3. For
this analysis, we focused on the ACA, AGA, BCB, and
BGB V1V2 chimeras that, as shown in Figure 2A, exhib-
ited a decreased functionality compared to the wild-type
receiver protein. To this end, we tested the ability to
mediate viral entry into target cells of chimeras where
the V1V2 and V3 sequences came from the same isolate
(V1V2/V3 chimeras; see Figure 1C). Apart from the
ACA chimera, for which a twofold (although not signifi-
cant; p = 0.09) increase in functionality was observed, in
none of the cases the insertion of the homologous V3
region in the V1V2 chimeras restored the functionality
of the simple V1V2 chimeras (p > 0.05) (Figure 3A). All
of the V1V2/V3 chimeras remained at levels of func-
tionality significantly lower (p < 0.05) than the corre-
sponding wild-type receiver proteins. Therefore, the
alteration of the functionality observed in the V1V2 chi-
meras does not seem to be due to the presence of a V3
domain from a different phylogenetic origin.
The observation that swapping of the V3 domain only
marginally affects the functionality of Env is also con-
firmed by the replacement of V3 alone (V3 chimeras,
Figure 1C). With V3 chimeras, the decrease in function-
ality of the envelopes was less marked than for the V1V2
chimeras. Indeed, no decrease was observed for two
cases, and for the other two, the decrease was limited to
50% (Figure 3B). The level of expression of the different
chimeras cannot account for the differences in function-
ality observed (Additional file 3: Figure S1, supplemen-
tary material).
The higher level of sequence identity of the V3 se-
quence (Figure 3C), which ranged from 62.9% to 88.6%
for the isolates used, the similarity of hydrophobicity
profiles and predicted glycosylation patterns (Figure 3D
and E) could explain the good tolerance to swapping this
domain between isolates.
Relative contribution of V1 and V2 domains to the
functionality of the chimeras
The V1V2 region is composed of two distinct domains,
V1 and V2 [31] that are bordered by a disulfide bond.
To evaluate the contribution of each of these two do-
mains to the observed decrease in functionality of the
V1V2 chimeric Env, we constructed chimeric Env pro-
teins carrying envelopes where only the V1 or the V2 do-
main was replaced (V1 and V2 chimeras, Figure 1C).
We focused on the five chimeras presented in Figure 2A.
All the V1 chimeras displayed a decreased functionality
with respect to the corresponding wild-type proteins
(Figure 4A). With the exception of the ABA chimera
(level of functionality of 44%), the residual functionality
was never above 15%. Concerning the V2 chimeras, theperturbation of the functionality was globally less dra-
matic. Indeed, the functionality of the AGA chimera did
not differ significantly from that of the wild-type back-
bone A protein, whereas for the ABA and ACA chi-
meras a significant (p < 0.05) reduction was observed,
albeit only by around a factor of two (Figure 4A). For
BCB and BGB chimeras, instead, swapping of V2 re-
duced the functionality to levels never above 3%. The
overall more limited perturbation of the activity ob-
served with the V2 chimeras can be accounted for by
the lower divergence of hydrophobicity profiles and pre-
dicted glycosylation patterns observed in this region with
respect to V1, for which important differences were ob-
served among the isolates (Figures 4B and 4C). Also in
this case, the level of expression of the various chimeras
could not account for the differences in functionality ob-
served (Additional file 3: Figure S1, supplementary
materials).
These results were then analyzed based on the crystal
structure of these domains, which was recently solved by
McLellan and colleagues [31]. The V1V2 region in com-
plex with the neutralizing antibody PG9 are composed
of 4 stranded anti-parallel β-sheet domains (Figure 1A).
According to that structure, the replacement of V1 from
cysteine to cysteine (126–157, HXB2 numbering) as we
have implemented in our chimeras, leads to the replace-
ment of β-sheet A, the V1 loop, and the beginning of β-
sheet B (Figure 4D). In the ABA, AGA, and BGB chi-
meras this results in changes restricted to the V1 loop
(Figure 1B), indicating that this loop is the one respon-
sible for the drop in functionality observed in these chi-
meras. For the other two V1 chimeras (ACA and BCB),
in addition to the V1 loop, one substitution (S vs T) was
also present in β-sheet A and one (I vs N) in the begin-
ning of β-sheet B (Figure 1B). Therefore, in these cases,
these substitutions may have contributed to the de-
creased functionality observed in these two chimeras. In
the case of the V2 chimeras, the most extensive se-
quence variation was due to the V2 loop even if, in this
case, more differences were observed also elsewhere,
particularly in β-sheet C (Figure 1B and Table 1).
Membrane fusion ability of the chimeric envelopes
To obtain insights into the nature of the defect in func-
tionality observed in the envelopes carrying an exogen-
ous V1V2, V1, or V2 region, the chimeras used thus far
in the present study were characterized in cell-cell fusion
assays. To this end, we used cells expressing the chimeric
envelope (producer cells, HeLa-Tat) and CD4+/CCR5+
TZMbl cells (target cells). This assay, which has been
previously described [65], consists in measuring the
extent of membrane fusion between producer and tar-
get cells through the ability of the chimeras to form
syncytia upon co-cultivation of these cells. The formation
Figure 3 Effect of the presence of homologous V1V2 and V3 regions on the functionality of the chimeric envelopes. Panel A.
Comparison of the functionality of V1V2/V3 chimeras with respect to V1V2 chimeras. The values for the V1V2 chimeras (from Figure 2A) are given as
a reference in black. Panel B. Functionality of V3 chimeras. Values are the average of 4 to 5 independent experiments in both panels. The asterisk
indicates a significant difference (p < 0.001) in the functionality of the chimera with respect to the corresponding wild-type receiver protein. Panel
C. Amino acid sequence alignment of the V3 region for the isolates used to generate the chimeras characterized in Panel B. Identical residues are in a
yellow background. The sequences are shown including the C residues that border the V3 region. Alignments were performed using MUSCLE 3.8
[55]. The percentage of identity between the isolates is given on the right of each alignment. Panel D. Hydrophobicity profile of the variable region
V3. The profile of the four sequences most intensively studied here (isolates A, B, C, and G) is given. The position in amino acids is given on
the x axis, with numbering starting from the first amino acid (N-ter) after the cysteine residue that marks the border of the C2-V3 transition.
Panel E. Potential N-Glycosylation sites of the variable region V3 for each subtype used. The location of N-glycosylation sites is indicated. Only
sites with a predicted N-glycosylation potential >0.5 according to Server NetNGlyc 1.0 [64] are shown.
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porter gene present in the target cells (see Methods).
The ability to mediate cell-cell fusion is given as a per-
centage relative to the wild-type receiver protein. Enve-
lopes positive for this test can thereby recognize the
receptor and coreceptor molecules as well as carry outmembrane fusion. The results obtained with this test
are given in Table 3 and are plotted in Figure 5 as a
function of the efficiency of viral entry.
The graph in Figure 5 has been divided into four parts
defined by whether the difference between the activity of
the chimeras and that of the wild-type backbone was
Figure 4 Implication of variable domains V1 and V2 in the loss of functionality of the chimeras. Panel A. Functionality of V1 and V2
chimeras. The values for the V1V2 chimeras (from Figure 2A) are given as a reference for comparison with the V1 and V2 chimeras. The values are
the average of 3 to 6 independent experiments. In all cases, the values are given relative to those observed for the corresponding wild-type
receiver protein. Panel B. Hydrophobicity profile of the variable regions V1 and V2. The profile of the four sequences most intensively studied here
(isolates A, B, C, and G) is given for V1 in red and for V2 in blue. The position in amino acids is given on the x axis, with numbering starting from
the first amino acid (N-terminal) after the cysteine residue that marks the border of the C1-V1 transition for V1 and the V1-V2 transition for V2.
Panel C. Potential N-Glycosylation sites of the variable regions V1 and V2 for each subtype used. The locations of the N-glycosylation sites with an N-
glycosylation potential >0.5, as predicted according to the Server NetNGlyc 1.0 [64] in V1 or V2 are indicated in the red and blue regions,
respectively. Panel D. Representation of the V1V2 region in the V1 or in the V2 chimeras according to the structure of McLellan et al. [31]. The
representation is as in Figure 1A. The colored part of the drawing corresponds to the parts that were replaced.
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cell fusion tests (horizontal and vertical bars, respectively).
Chimeras falling in the blue section of the graph were
significantly less functional than the wild-type backbone
proteins in both entry and cell-cell fusion tests (p < 0.05),
which is therefore indicative of an intrinsic defect of the
proteins. The red section comprises chimeras whose de-
fect in viral entry tests was relieved in the cell-cell entry
assay. This result can be indicative of increased shed-
ding of the chimeric gp120 from the viral particle, since
such a defect would be compensated in the cell-cell
fusion assay by the continuous production of Env mol-
ecules in the producer cells. Chimeras in the green
section correspond to proteins that retained a level of
functionality not significantly different from that of the
corresponding wild-type protein in the viral entry assay as
well as in the cell-cell fusion test.
Theoretically, no chimeras should fall in the gray sec-
tion, since envelopes that promote membrane fusion in
the context of the viral particle are also supposed tosupport membrane fusion in the less stringent cell-cell
fusion assay. Despite this, the AGA V2 chimera does
fall in this region. This observation is explained by the
defect, observed by western blot, in the expression of
this chimera in the cells used for the cell-cell fusion
assay (HeLa-Tat), but not in the viral particles used for
the viral entry test, which were produced by HEK 293T
cells (see Additional file 3: Figure S1 and Additional
file 4: Figure S2). Apart from this case, none of the differ-
ences in the levels of functionality of the chimeras in the
cell-cell test could be accounted for by their levels of
expression (Additional file 4: Figure S2).
Discussion
Genetic diversity is crucial for HIV escape from the host
immune response. As the most external portion of the
viral particle, gp120 is the component of the virus most
exposed to immune pressure and, consequently, the
protein for which genetic diversification likely has the
utmost importance. In addition, gp120 is the sole target
Table 3 Cell-cell fusion assay values of V1V2, V1, and
V2 chimeras
Cell-cell fusion (%) SD (%)
V1V2 ABA 131.5 59.9
ACA 90.4 39.7
AGA 108.0 18.1
BCB 84.6 16.0
BGB 50.7 18.0
V1 ABA 133.0 51.6
ACA 120.1 52.9
AGA 93.5 28.1
BCB 49.8 15.1
BGB 14.6 8.2
V2 ABA 120.5 29.3
ACA 138.3 56.6
AGA 35.1 12.7
BCB 61.8 17.1
BGB 4.8 6.4
In all cases, the values are given relative to those observed for the corresponding
wild-type receiver protein. The results represent the mean values derived from at
least three independent experiments. SD, standard deviation.
Figure 5 Correlation between cell-cell fusion and viral entry for
envelopes carrying an exogenous V1, V2, or V1V2 region. Values
are the average of 3 to 5 independent experiments for viral entry
assays or the average of 3 independent experiments for cell-cell fusion
assays. The graph is divided into four sections according to whether
the proteins located in one quarter displayed or did not display a level
of functionality significantly lower than that of the corresponding wild-
type protein in viral entry or in cell-cell fusion assays. The threshold of
significance is set at p < 0.05, as indicated in the figure (ns = not
significant). The bars indicating the threshold of significance are drawn
in the median position between the position of the last sample that
has a significant decrease in functionality and the first one that does
not display a significant difference (gray circle and green diamonds for
cell entry; blue diamonds and red triangle for cell-cell fusion). V1V2
chimeras, diamonds; V1 chimeras, circles; V2 chimeras, triangles.
Chimeras: ABA, gray, ACA, yellow; AGA, green; BCB, red; BGB, blue.
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http://www.retrovirology.com/content/10/1/114of neutralizing antibodies thus far identified, and the
recent RV144 vaccine trial has shown that the V1V2 of
gp120 is the main region involved in the escape from
the immune response [45-47]. Although no crystal struc-
ture of the entire gp120 protein, including all the variable
regions, is available to date, electron tomography, cryoe-
lectron microscopy and analysis of the crystal structures
with the variable regions deleted support the view that the
variable regions emanate from the central core composed
of the constant portions of the protein [43]. The location
of these regions on the external portion of the protein and
their extensive sequence diversity suggest that they might
undergo only minor structural constraints and that they
have evolved to maximize their possibility of sequence
diversification while preserving the functionality of the
protein. Despite these considerations, we observed here
that the replacement of the V1V2 region of a given Env
of a primary isolate with the V1V2 region of a functional
Env from a different primary isolate reduced the func-
tionality to almost undetectable levels in 7/12 cases stud-
ied (Figure 2B). With the exception of the G/G1 chimera
that displayed an increased functionality (Table 2), the
remaining chimeras displayed levels of functionality com-
parable to those of the corresponding wild-type backbone
proteins. Overall, the functionality of Env was perturbed
at comparable levels in intra- and intersubtype chimeras.
The latter finding underscores the observation that inter-
ference with envelope functionality is not limited to the
relatively rare case of chimeras involving isolates from dif-
ferent HIV-1 subtypes but has broader validity. Globally,
the chimeras tended to have a decreased functionality
with respect to the corresponding wild-type proteins, sug-
gesting that, as shown for the case of single amino acid
mutants of this gene in previous studies [66-68], chimeric
envelopes mostly undergo purifying selection.
Several lines of evidence support a close association
between V1V2 and V3 regions. Their implication in the
formation of an interacting surface between monomers,
or at least their close spatial proximity within the trimer,
has been supported by the identification of broadly neu-
tralizing antibodies that recognize an epitope present only
in the trimeric form of gp120. This epitope is constituted
partially of V1V2 and partially of V3 [63,69]. In addition,
V1V2 and V3 jointly protect neutralization-sensitive epi-
topes that are recognized by cross-neutralizing plasma by
creating a shield that has been suggested to result from
the juxtaposition of the V1V2 region from one subunit
of the Env trimer with the V3 region from another sub-
unit [62]. Relevant to this work, the spatial proximity
between V1V2 and V3 raised the issue of a possible co-
evolution between the V1V2 and V3 regions that could
be responsible for the decreased functionality observed
for some of our V1V2 chimeras. The results we report
here, however, do not support this view because, in the
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V1V2 and V3 from the same isolate did not preserve
Env functionality, which remained in the range of what
was observed for the simple V1V2 chimeras (p > 0.5 in
all cases, Figure 3A). However, the lack of restoration of
functionality of Env could also simply reflect the fact
that the simultaneous replacement of the V1V2 and V3
regions was not sufficient to obtain their reciprocal proper
orientation in the context of the exogenous backbone
protein.
In line with the view of limited involvement of V3 in
the mechanisms leading to the decreased functionality
of the chimeric envelopes studied here, the replacement
of V3 alone globally had less dramatic consequences on
the functionality of Env compared with that observed
for the V1V2 chimeras. The higher level of sequence
conservation of V3 [1], which likely reflects the selection
for maintaining an optimal conformation of the corecep-
tor binding site, [43] could explain why the replacement
of this domain is better tolerated than that of V1V2. A
higher similarity among the V3 than V1V2 domains was
also observed at the levels of hydrophobicity, pattern of
potential glycosylation sites, and overall size observed
between V3 and V1V2 regions (Figure 3, panels D and E).
Several of our V1V2 chimeras presented defects in the
viral entry assays that were relieved in the cell-cell fusion
test (Figure 5). A possible explanation for such a pheno-
type is that the chimeras present a decreased stability of
the gp120/gp41 complex, defect that would be compen-
sated in the cell-cell fusion assay by the continuous pro-
duction of Env that migrates at the cell surface. V1 and
V2 are in a crucial position for the arrangement of the
N- and C-terminal domains, which are involved in the
formation of the interface of gp120 contacting the gp41
[70,71]. This situation could potentially influence the
stability of the interaction between gp120 and gp41.
In the present study, the replacement of the V1 or V2
domains alone provided important insights for under-
standing which parts are involved in the perturbation of
the functionality of the V1V2 chimeric envelopes. The
structure of the V1V2 region in complex with the broadly
neutralizing antibody PG9 has been recently solved, re-
vealing an organization in four, fairly conserved, antiparal-
lel β-sheets and two non-structured loops that present the
strongest genetic diversity (Figures 1A and 1B and [31]).
Even if it is difficult to distinguish the contribution of V1
independently from that of V2, and vice versa, because
the replacement of only one domain might trigger an
alteration of the folding of the other, our results shed
light on a central role for V1 in the determination of
the functionality of the chimeras. These results provide
a frame for future works aimed at understanding the
structural reasons for the interference of genetic diversity
in this region with the functionality of the envelope.Conclusion
The present study shows that the genetic diversification
of the thus far poorly characterized V1 domain is re-
stricted by unsuspected strong functional constraints.
Given the extensive diversity of this region in the popu-
lation and its central role in the immune control of infec-
tion, a better understanding of the architectural organization
of V1, as well as that of V2, constitutes an important
area for understanding the evolutionary trajectories of
this region. The perturbation exerted by the variable re-
gions on the structural requirements for retention of Env
functionality could define potential new antiviral targets
on this protein, crucial for viral infection.
Methods
Cells
HEK 293T, 293T CD4+CCR5+, HeLa-Tat, and TZMbl
cells were cultured in Dulbecco's modified Eagle's medium
supplemented with 10% fetal calf serum, penicillin
(100 UI/ml), and streptomycin (100 μg/ml) (Invitrogen,
Carlsbad, NM, USA). The cells were maintained at 37°C
with 5% CO2.
Viral sequences and accession numbers
The parental sequences used were primary isolates from
subtypes A, B, C, and G. Three isolates from subtype A
(GenBank accession numbers AF407156, AF407160 and
AF407148), referred to in the present work as A, A1, and
A2, respectively; one isolate from subtype B (GenBank
accession number: AY835448); four isolates from subtype
C (GenBank accession numbers DQ435683, DQ435682,
DQ388514, and DQ388515), referred to as C, C1, C2, and
C3, respectively; and two isolates from subtype G, G-548
and GenBank accession numbers: AM279346, referred to
as G and G1, respectively. All of the viral sequences
were provided by the NIH, through the AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID,
NIH, except the isolates G-548, which was a kind gift from
M. Peeters (Institut de Recherche pour le Développement,
Montpellier, France) and AM279346 [72], for which the
V1V2 region (the region used in the present study) was
synthesized chemically by GenScript (Piscataway, NJ, USA).
Construction of chimeric envelopes
Env chimeras were generated using an overlapping PCR
procedure as previously described [54]. Three independent
PCR amplifications have been performed to amplify the
region to replace (V1V2, C2, and V3), as well as regions
located upstream (5′ region) and downstream (3′ region).
A subsequent PCR amplification to reconstitute the 5′
region of the gene with the region replaced was per-
formed, and a final PCR amplification will reconstitute
the entire chimeric env gene. For the final reconstitu-
tion, 200 ng for each region of the PCR products was
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30–40 nt. These PCR amplifications were performed
using Phusion DNA polymerase (Finnzymes, Espoo, Finland)
for 30 cycles. The reconstituted PCR products were gel
purified and then cloned into the commercial directional
vector pcDNA3.1D-Topo according to the manufacturer’s
instructions (Invitrogen, Carlsbad, NM, USA). All of the
construct sequences were verified by sequencing (GATC
Biotech, Konstanz, Germany), and the expression and pro-
cessing of all of the chimeras were verified by Western
blotting and immunoprecipitation. The swapped domains
were defined by the cysteine residues delimiting the V1,
V2, and V3 loops. Precisely, the borders of the swapped
domains were as follows: 126–196 for V1V2, 126–157 for
V1, 157–196 for V2, 196–296 for C2 and 296–331 for V3,
where the numbering refers to the amino acids of the
gp120 protein of HXB2.
Entry assay
HEK 293T cells were transfected using the standard cal-
cium phosphate method with the pNL4.3 env- luc+ provirus
and another plasmid (pcDNA3.1D-Topo-env) carrying the
parental or chimeric envelope glycoproteins. pcDNA 3.1D-
Topo with no insert was used as a negative control, and a
pcDNA3.1D-Topo-env with the envelope from the strain
ADA was used as a positive control. Two days post-
transfection, the viral particles produced were filtered on
0.45 μM filters, and 50 ng of p24 antigen of each viral
preparation was used to transduce 2.5 × 105 HEK 293T
CD4+ CCR5+ cells [54]. All viral solutions were normal-
ized using an enzyme immunoassay for detection of the
p24 antigen (Innotest HIV Antigen mAb, Innogenetics,
Gent, Belgium). Forty-eight hours after transduction, the
medium was removed, cells were washed twice in PBS,
lysed, and centrifuged. The supernatant was used to meas-
ure luciferase activity according to the manufacturer’s
protocol (Promega, Fitchburg, WI, USA) with a Glomax
luminometer (Promega, Fitchburg, WI, USA).
Cell-cell fusion
In this assay, HeLa-Tat cells expressing the Tat protein,
which is necessary for the transcriptional activation of
HIV-1, were transfected using the calcium phosphate
method with a pcDNA3.1 Topo plasmid carrying the
envelope protein to test (chimeric, positive, and negative
controls mentioned in the entry assay). Two days later,
1.5 × 105 of these cells, expressing envelope proteins
at their surface, were co-cultivated in a CO2 incubator
at 37°C in 12-well plates with 4.5 × 105 cells/well of
TZMbl cells containing the luciferase reporter gene under
the control of the HIV-1 promoter. After 24 hours of co-
cultivation, cells were detached with trypsin and washed,
and the same procedure as for the entry assay was
followed to lyse and measure luciferase activity.Western blot analysis
The expression of wild-type and chimeric proteins was
verified by western blotting on the viral particles used
for viral entry test and on the cells (expressing the enve-
lopes) used for the cell-cell fusion assay (HeLa-Tat).
For each sample, culture supernatants of transfected
HEK 293T cells (containing the viral particles) were fil-
tered through a 0.45 μM filter and viral particles were
purified by centrifugation at 130,000 × g for 2 hours through
a 20% sucrose cushion. Viral pellets were then solubilized
and lysed in RIPA buffer (1× PBS, 1% NP-40, 0.5% sodium
deoxycholate, 0.05% SDS). All viral solutions were nor-
malized for p24 antigen content, determined by ELISA
(Innotest HIVAntigen mAb, Innogenetics, Gent, Belgium).
HeLa-Tat cells used for the cell-cell fusion assay were
washed with 1× concentrated phosphate-buffered saline
(PBS) and lysed in RIPA buffer for 15 min on ice. Cell
lysates were then centrifuged at 12,000 × g for 20 min at
4°C and the supernatants were recovered for use. Total
protein concentrations were normalized for each sample
by Bradford assay following the instructions of the Biorad
Protein assay (Biorad, CA, USA).
Each sample containing 30 ng of p24 (for western
blots on viral particles) and 60 μg of total proteins (for
western blots on HeLa-Tat cells) was loaded and separated
by electrophoresis in a 4-12% NuPAGE Bis-Tris gel
(NuPAGE Novex, Thermo Fisher Scientific, MA, USA).
Proteins were then transferred to a polyvinylidene difluor-
ide (PVDF) membrane and blotted with a pool of sera
from group M HIV-1 infected individuals (kind gift of
J. Mak, Burnet Institute, Melbourne, Australia), followed
by horseradish peroxidase (HRP) conjugated sheep poly-
clonal anti-human IgG (GE Healthcare Life Sciences,
Little Chalfont, UK) and also by HRP-conjugated mouse
IgG anti human β-actin (Sigma-Aldrich, St Louis, MO,
USA) for blots relative to samples of the cell-cell fusion
assay. Immunoblots were revealed using a luminol based
enhanced chemiluminescence substrate (Pierce ECL Plus
western blotting substrate, Thermo Fisher Scientific,
MA, USA).
Comparison of functionality levels between chimeric
envelopes
The significance of the differences between the levels of
functionality of chimeric envelopes was tested using
Student’s t-tests by comparing the levels observed for
each chimera relative to the level of the wild-type protein
providing the backbone. When comparing a chimeric
envelope with the wild-type protein that provided the
backbone, the levels of functionality of the two proteins
being compared were calculated relative to the level of
functionality of the reference positive control (HIV-1
ADA Env). The significance of the correlation coeffi-
cients was inferred by computing t values with the
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constant, and N is the number of samples.
Sequence alignment and estimates of sequence identity
Sequence alignments for the estimate of sequence identity
were constructed using MUSCLE 3.8 [55] and manually
refined to improve alignment, particularly in regions where
the sequence length varied and/or the homology was low,
using Mega5 [73]. Sequence identity was calculated pair-
wise as the fraction of exactly matched nucleotides along
the length of each alignment.
Additional files
Additional file 1: Table S1. Level of functionality of the chimeras with
respect to that of both parental wild-type proteins. The values are given
as percentage. SD, standard deviation.
Additional file 2: Table S2. Sequence similarity of the different
structural components of the V1V2 region for the chimeras studied.
Results are based on the structure described in reference [31]. The values
of sequence similarity have been calculated according to the BLOSUM 62
matrix. The individual regions are defined as in Figure 1A.
Additional file 3: Figure S1. Expression of wild-type and chimeric
envelope proteins in viral particles. Viral particles were collected 48 h
post-transfection and purified on sucrose cushion. Normalized amounts
of total viral proteins (based on p24 quantification) were analysed by
western blotting using a pool of sera from groupe M HIV-1-infected
individuals (kind gift of J. Mak, Burnet Institute, Melbourne, Australia).
Panels A, B, C, D, and E correspond to ABA, ACA, AGA, BCB and BGB
chimeras, respectively. Positive and negative controls (+ and – signs in
the figure) were constituted by viruses containing T-ADA envelope
coding plasmid and by viruses obtained after transfection with an empty
pcDNA3.1 + pNAL4.3Env- plasmids, respectively. The subtype of the two
wild-type proteins used to produce the chimeras and the region
replaced are indicated on the top of each panel. Panel F. Western blot of
the V1V2/V3 chimeras (see Figure 3A). Parental proteins as well as
positive and negative controls are as in panels A-F. In all panels, the
bands corresponding to gp120, gp41 and p24 are indicated with arrows.
Differences observed between wild-type proteins (A, B, C and G) in the
figures could reflect differences either in their level of expression or in
the efficiency of their recognition by the sera.
Additional file 4: Figure S2. Expression of wild-type and chimeric
envelope proteins in HeLa cells. 24 h post-transfection, equalized amount
of proteins of HeLa cells lysates (expressing viral envelope proteins) were
analysed by western blotting using a pool of sera from group M HIV-1-infected
individuals (as for Additional file 3: Figure S1) and by anti β-actin
antibody after stripping the membranes. Panels A, B, C, D, and E
correspond to ABA, ACA, AGA, BCB and BGB chimeras, respectively.
Positive and negative controls (+ and – signs in the figure) were
constituted by cells transfected with the T-ADA envelope coding
plasmid and by cells transfected with an empty pcDNA3.1 + pNAL4.3Env-
plasmids, respectively. The name of each sample is given as for Additional
file 3: Figure S1 and the positions of the bands corresponding to the gp120,
the gp41, and the β-actin protein is indicated by arrows.
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